BACKGROUND: For patients with peripheral arterial disease (PAD), depression is associated with worse patency and recurrent symptoms in the treated leg, but its association with death or cardiovascular events in other vascular beds is unknown. OBJECTIVE: To assess the association between depression and mortality or cardiovascular events outside the affected leg after PAD revascularization. DESIGN: Retrospective cohort study. SUBJECTS: Two hundred fifty-seven consecutive patients undergoing lower extremity revascularization for symptomatic PAD at a single institution between January 2000 and May 2005 were included in this study. By protocol, patients were previously screened for depression and diagnosed by the primary care provider. MEASUREMENTS: The outcomes evaluated included a composite of death or major adverse cardiovascular events (MACE; coronary heart disease, contralateral PAD, or cerebrovascular event) as well as major outcome categories of death, coronary heart disease, contralateral PAD, or cerebrovascular events. RESULTS: At revascularization, 35.0% patients had been diagnosed with depression. Those with depression were significantly younger and more likely to use tobacco. By life-table analysis, patients with depression had significantly increased risk for death/MACE, coronary heart disease, and contralateral PAD events, but not cerebrovascular events or death. By multivariate analysis, patients with depression were at significantly increased risk for death/MACE (hazard ratio [HR] = 2.05; p < .0001), contralateral PAD (HR = 2.20; p = .009), and coronary heart disease events (HR = 2.31; p = .005) but not cerebrovascular events or death. CONCLUSIONS: Depression is common among patients undergoing revascularization for symptomatic PAD. After intervention, patients with depression are at significantly increased risk for coronary heart disease events and progression of contralateral PAD. Prospective analysis is required to confirm these results.
BACKGROUND: For patients with peripheral arterial disease (PAD), depression is associated with worse patency and recurrent symptoms in the treated leg, but its association with death or cardiovascular events in other vascular beds is unknown. OBJECTIVE: To assess the association between depression and mortality or cardiovascular events outside the affected leg after PAD revascularization. DESIGN: Retrospective cohort study. SUBJECTS: Two hundred fifty-seven consecutive patients undergoing lower extremity revascularization for symptomatic PAD at a single institution between January 2000 and May 2005 were included in this study. By protocol, patients were previously screened for depression and diagnosed by the primary care provider. MEASUREMENTS: The outcomes evaluated included a composite of death or major adverse cardiovascular events (MACE; coronary heart disease, contralateral PAD, or cerebrovascular event) as well as major outcome categories of death, coronary heart disease, contralateral PAD, or cerebrovascular events. RESULTS: At revascularization, 35.0% patients had been diagnosed with depression. Those with depression were significantly younger and more likely to use tobacco. By life-table analysis, patients with depression had significantly increased risk for death/MACE, coronary heart disease, and contralateral PAD events, but not cerebrovascular events or death. By multivariate analysis, patients with depression were at significantly increased risk for death/MACE (hazard ratio [HR] = 2.05; p < .0001), contralateral PAD (HR = 2.20; p = .009), and coronary heart disease events (HR = 2.31; p = .005) but not cerebrovascular events or death. CONCLUSIONS:Depression is common among patients undergoing revascularization for symptomatic PAD. After intervention, patients with depression are at significantly increased risk for coronary heart disease events and progression of contralateral PAD. Prospective analysis is required to confirm these results.
Authors: Joost P van Melle; Peter de Jonge; Titia A Spijkerman; Jan G P Tijssen; Johan Ormel; Dirk J van Veldhuisen; Rob H S van den Brink; Maarten P van den Berg Journal: Psychosom Med Date: 2004 Nov-Dec Impact factor: 4.312
Authors: B W Penninx; A T Beekman; J Ormel; D M Kriegsman; A J Boeke; J T van Eijk; D J Deeg Journal: J Psychosom Res Date: 1996-05 Impact factor: 3.006
Authors: Manish K Jha; Arman Qamar; Muthiah Vaduganathan; Dennis S Charney; James W Murrough Journal: J Am Coll Cardiol Date: 2019-04-16 Impact factor: 24.094
Authors: S Marlene Grenon; Beth E Cohen; Kim Smolderen; Eric Vittinghoff; Mary A Whooley; Jade Hiramoto Journal: J Vasc Surg Date: 2014-03-22 Impact factor: 4.268
Authors: S Marlene Grenon; Jade Hiramoto; Kim G Smolderen; Eric Vittinghoff; Mary A Whooley; Beth E Cohen Journal: J Am Heart Assoc Date: 2012-08-24 Impact factor: 5.501
Authors: Rachel P Dreyer; Moniek van Zitteren; John F Beltrame; Robert Fitridge; Johan Denollet; Patrick W Vriens; John A Spertus; Kim G Smolderen Journal: J Am Heart Assoc Date: 2014-12-23 Impact factor: 5.501
Authors: Mary M McDermott; Jack M Guralnik; Lu Tian; Melina R Kibbe; Luigi Ferrucci; Lihui Zhao; Kiang Liu; Yihua Liao; Ying Gao; Michael H Criqui Journal: J Am Heart Assoc Date: 2016-03-18 Impact factor: 5.501
Authors: Qurat-Ul-Ain Jelani; Carlos Mena-Hurtado; Matthew Burg; Robert Soufer; Kensey Gosch; Philip G Jones; John A Spertus; Basmah Safdar; Kim G Smolderen Journal: J Am Heart Assoc Date: 2020-08-12 Impact factor: 5.501